Pfizer Inc. (NYSE:PFE)
Bands
Volume
200 SMA
50 SMA
20 SMA
Videos
Alerts
Articles
Events
Old Forum Content for PFE
Make a Forum Post Become a member to view recent forum posts. Already a member? Sign in here.
- woodman: $PFE $SRPT - Pfizer's DMD Phase 3 fail leaves SRPT (PDUFA 6/21) as the only game in town. https://www.fiercebiotech.com/biotech/pfizers-phase-3-gene-therapy-trial-fails-improve-function-boys-duchenne-muscular-dystrophy
- joelsg1: @woodman $PFE $SRPT Never liked $SRPT on MD since it got the nod over $BMRN, word then was it was close but FDA approved $SRPT to give some hope to families affected by MD, not that their drug worked that well. Tough nut to crack.
- woodman: @joelsg1 $PFE $SRPT $BMRN - I have no skin in the DMD TA. I think it will be approved, but it may have a strict/limiting label. The testimony of parents whose kids have improved quite a bit is compelling.
- woodman: $PFE - Nearing the overhead 200d. It's had a definite change in complexion over the last almost 3 weeks.
- Motorman: @woodman $PFE Also 50Week. Starting a small position to add to as it gets through both.
- bwcarnation1: @Motorman $PFE I did the same
- mopick: @woodman $PFE Seagen purchase was a good one, should expand their oncology pipeline in the future.
- woodman: @mopick $PFE - It should buy or partner with $VKTX for an obesity play, in my humble opinion. :-)
- Geewhiz: @joelsg1 $NVDA 25B $GOOGL 12.4B : $PFE 5.7B: $MSFT 7.5B: $META 2.6B
- woodman: $PFE - continuing the discussion from earlier about this move higher from massive pullback, PFE has announced a plan to cut even more costs. It had already started a $4B savings strategy. Now it is planning on a new $1.5B round of cost savings. The market must like it. https://www.msn.com/en-us/money/companies/pfizer-plans-to-cut-costs-by-15-billion-as-demand-for-covid-vaccine-dwindles/ar-BB1mSieQ?ocid=BingNewsSerp
- joelsg1: @Geewhiz $NVDA $GOOGL $PFE $MSFT $META We'll have to rethink what constitutes a "big" move.
-
StockMarketMentor: ...
I think this is a pretty interesting market because of the relatively low barrier to entry. There isn't just one patent such as the situation with Pfizer ($PFE) back in the day when the little blue pill was completely owned by Pfizer. Here, there ... - joelsg1: @woodman $VKTX $PFE $MRK $JNJ $REGN $RHHBY (Roche) in the game as well with early results this am.
- Bs7518: @woodman $VKTX $PFE $MRK $JNJ $REGN Thank you for sharing its helps me stay clear on what i'm doing. You ROCK:)
- woodman: $PFE change of complexion.
- joelsg1: @woodman $PFE Rosacea? :)
- SusanW: @woodman $PFE I have bought and sold PFE and made money. I am now in again hoping the $SGEN combination takes off.
- woodman: @SusanW $PFE $SGEN - I'm *hoping* PFE enters into a collaboration/agreement with (if not a buyout of) $VKTX for the obesity drug. But the $43 billion buyout of SGEN is a big weight on PFE's books and could limit PFE's ability to do other big deals. That's why a parternship of some sort may be more palatable for PFE since buying VKTX may be more than it would want to spend now. But I think there are multiple potential suitors for VKTX.
-
woodman: ...
All this speculation wouldn't be complete without speculating about who would buy or partner with VKTX. Many have speculated $PFE. I don't think so because it still has to digest all that SGEN debt on the books, and there are other BPs with more ... - Geewhiz: @woodman $VKTX $PFE $MRK $JNJ $REGN Thank you for these thoughts. Holding $ARDX and $VKTX since you first mentioned. Much appreciated and much appreciate your sharing. Pardon that pun! ;-)
- DavidK: @Lou $CLSK $VKTX $DBRG $FTI $EPD I am positioning to some selling next week . Money managers gonna hold thru end of quarter and then sell some next week or so . I am only long $CLL ( small ) $PFE calls medium , small $ TLRY . Long VXX calls
- champ: @DavidK $CLSK $VKTX $DBRG $FTI $EPD $CLL $PFE ....The way that it normally works is....money managers don't sell in a strong Market...plus they will hold into the first earnings reports from the Banks...and that starts on 4/12...... ....plus they are not going to miss a strong earnings season, they will at least wait to see how earnings reports go..... however small traders might move off...but Not the money managers, thats my guess.
- DavidK: @champ $CLSK $VKTX $DBRG $FTI $EPD $CLL $PFE good catch . I did forget about this being an earnings report month . Probably small fry’s like me selling some stuff . I don’t like to hold thru earnings unless I really feel confident. $CCL I had a big call position about 2-3 days before earnings but bailed . I didn’t like price action
- Cheezit: @DAN Hi Dan $CART $PFE $TOST Please and Thank You..
- DavidK: $PFE - sold earlier today for 53% 1 week gain on calls . Up another 10% from my sell point . Does it stall here or go to 30 ? Josh Brown has been buying for a couple weeks and now he might be about even .
- DavidK: $PFE - Josh Brown was touting this yesterday ( actually the last few weeks ) and then another analyst later in the day. I bought 20 Sept 27.50 calls yesterday .
- phgruver: @TraderGeekSam $PFE Your post got me looking at $PFE again. I've been very disappointed that they haven't bottomed out, yet. Like you, I don't think $PFE is going out of business. While I agree with others that the COVID vaccines and boosters were poorly handled, to say the least, $PFE has a lot more than that in their warehouse. With a dividend of 6.49%, they are worth considering in a long term portfolio. A note of caution, though. For the last 2 qtrs, earnings did not cover the dividend, although for the full year, they are OK. That said, I did add a bit more to my holdings at $25.80.
- TraderGeekSam: $PFE trades like it's going out of business, but it's not. The pipeline is brewing with opportunities, and although it's is in a steep downtrend, at $25.85, this very cheap pharma stock is ripe for at least a robust countertrend bounce. As a portfoli ...
- woodman: @TraderGeekSam $PFE - Can it spare $30B for $VKTX? :-)
- DavidK: @woodman $PFE $VKTX not a bad idea . Looks like thier only hope near term is for them to team up with the govt and run another Covid lockdown .
- bigbartabs: @TraderGeekSam $PFE ... the chart looks like blood pouring out of a broken heart.
- Margi1983: $PFE. This massive Pharma company reached a low today not seen since 2013. They still have very high gross margin, but awful sales contraction and earnings reductions. At some point $PFE with a 6% divi will be a buy, possible a great LT investment. Maybe at 22. Thoughts??
- sierramp: @Margi1983 $PFE I wouldn't touch it until the 8D, 21D and 50D are in the right order.
- TraderGeekSam: @woodman $PFE $VKTX I doubt it. The acquisition of Seattle Genetics might have left the kitty a little bare. :-)
- TraderGeekSam: @Margi1983 $PFE See my earlier post about buying a chunk of PFE for my clients and myself today. This is a long-term position, not a trading position. I'm oftentimes early, but usually right when I've been this patient. I did the same with $TGT, $DELL, $STX, $WDC and many others that were being some like they were going out of business. PFE has a solid future.
- woodman: @DavidK $VKTX $LLY - I think they all do to some extent. I don't know how it compares. Don't over think it. Obesity is a HUGE Total Addressable Market. $100B or more annually by 2030. Most of LLY's $760B market cap is due to its obesity/diabetes med ...
- woodman: @RD $LLY - "Overweight" (haha). It has the best obesity med on the market. $VKTX will get a piece of that pie with one that is as good or better and that is safer. But I don't think VKTX will be around to market it itself. I think a BP competetor like $PFE will snap VKTX up eventually. I could see it happening this year. There's "room" for both in the portfolio. I have both.
- woodman: $VKTX through $30, now through $31. Racing to Q1 data for oral obesity med (which isn't really my focus but certainly curious) and subcutaneous obesity (which is my focus). CEO was talking positively about a Phase 3 trial plan for subQ obesity med VK ...
- phgruver: @woodman $VKTX $LLY $NVO $PFE $AMGN You're loosing sight of the fact that this is primarily a treatment for Type-2 Diabetes. Currently, it has to be administered as a shot. If they can convert it to an effective pill, the market is huge! Weight loss is a bonus, but most Type-2 Diabetics are also overweight, so there's a lot of overlap. And, yes, you are correct, in order to bring it to market $VKTX will have to partner with, or sell out to a large pharma.
- woodman: $VKTX earnings/updates conference call 2/7 amc. https://ir.vikingtherapeutics.com/2024-01-31-Viking-Therapeutics-to-Report-Financial-Results-for-Fourth-Quarter-and-Year-End-2023-on-February-7,-2024 I have no idea if they will report any data at at that time. I've not seen any statements on that. All I have seen is that Phase 1 oral obesity drug data are expected 1Q24 and subq obesity drug data are expected 1H24. So any time, particularly for oral version. Manking things more interesting are buyout rumors, with $PFE's name being thrown around as a suitor. See https://seekingalpha.com/news/4060945-viking-therapeutics-gains-amid-takeover-speculation I'm not in this because I foresee an imminent buyout. I'm just letting things unfold with the data, etc. Eventually, if things keep going well, I expect a buyout, but imminently, who knows.
- DavidK: $PFE- my calls getting wacked . Thanks Josh Brown for steering me to this pos . Anyone have opinions on this chart . I had mine and so far wrong . I am like the fox who broke off the love affair with the skunk 🦨, he had not had all he wanted just all he could stand .
- woodman: $VKTX broke out last week, then sideways last few days. Now making a little flag. It is extended from the 50d and 200d with the 50 going to cross above the 200d soon. Shorter term, the 8dEMA has caught up again. It has oral and subq obesity drug cand ...
- bigbartabs: @DavidK $PFE ... I would sell and wait for it to recover the 20dma, and the 8dema.
- joelsg1: @woodman $VKTX $LLY $AMGN $PFE You are kinda the expert around here :)
- joelsg1: @DavidK $PFE Don't buy anything pitched on tv, at least not immediately. There is always a reason why the producers decide to show it to you. Doesn't make them crooks, just reality. On chart, the adage applies: 'Nothing good happens under the 200d'.
- phgruver: @DavidK $PFE As a short term trade or swing trade, I think there are better candidates. As a long term, income producing hold, $PFE still looks pretty good. The yield is up to 5.85%. The recent low was $25.76, but you don't want to give it that much space. As long as it holds above $28, I think you can own it.
- woodman: @joelsg1 $VKTX $LLY $AMGN $PFE https://i.gifer.com/1VF5.gif
- DavidK: @bigbartabs $PFE just sold before I saw your post . Thanks bought more $ TLRY. These pot stocks ($TLRY actually has lots of alcohol brands ) are spring loaded . There seems to be some encouraging developments regarding govt release of some studies . I like Tilray ceo as well . Good track record
- DavidK: @phgruver $PFE I had March calls that’s why I didn’t want to hold much longer . I usually don’t buy based on Tv touts but when I looked at the chart I thought it might be a candidate for a bounce and I quick trade.
- joelsg1: @woodman $VKTX $LLY $AMGN $PFE More hair than I'd imagine.
- woodman: @joelsg1 $VKTX $LLY $AMGN $PFE - Am I not using my nose-hair scissors (that I told @bigbartabs about) enough?
- phgruver: I'm not seeing much to do, today, but one thing of note: If $PFE holds yesterday's low of $28.27, this may be a good place to add in a LT account. $BMY also looks good right here for an income producing portfolio. Both of these are lagging their peers $ABBV, $GSK, $LLY & $MRK, so I expect them to play catch up.
- DavidK: $PFE- well it’s down $1 since Josh Brown recommended it a few days ago . I have March 29 calls . Might add around this level . On anther note , no way Fed drops rates anytime soon unless it’s in the Tank for Biden trying to juice markets even more . They didn’t work this hard trying to tame inflation to just drop rates .
- DavidK: $PFE - Josh Brown buying based on change in technicals . He went Thru a lot of reasons . I bought some March Calls . I don’t like the company and CEO at all but might be some Money to be made short term .
- Margi1983: @woodman $CLRB Thanks for the update. Long with modest position. You really know your biotech stuff. These others are not really biotech but I am also long $VRTX, $LLY, $NVO, and $PFE in the pharma space
- woodman: @Margi1983 $CLRB $VRTX $LLY $NVO $PFE - I won't hold all my shares through, but I still need to decide how much I will hold through. It's risky for sure. I can't imagine the company would be promoting this data so much into the presentation(s), but crazy stuff happens in BioLand. It could be a disappointment even if "good" or just simply an immediate sell the news. One never knows.
- camaro69: @phgruver $PFE $XLV Thanks for your post! This has been an easy one to hold since you posted
- Onthemark: $PFE breaking above 50d, would wait for pullback. Don't trust breakouts, better to buy bounces.
- Wolf: @Onthemark $PFE $ABBV is breaking out as well. Tagged the upper BB on decent volume. No position.
- Margi1983: $PFE reached a 10 year weekly low of $25.76 on 12/12/23. For my #LTInvestment account, I went long that day at 26.32. Now moving above the 50 ma today which is 29.47. Has 5.8% divi. This is LT value play. Revenue guidance for 2024 is quite flat, but EPS are expected to increase by 24% ( EPS from 1.45 -1.65 in 23 to 2.05-2.25 in 2024). $PFE needs to hold the 50 ma. Guidance for 2024 link here https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-full-year-2024-guidance
- DavidK: @Margi1983 $PFE #LTInvestment well it is an election year and another pandemic could be brewing up just in time for another mandated school closings , business shutdowns , vote from home and another vaccine from Pfizer that doesn’t work as advertised .
- woodman: @DavidK $PFE #LTInvestment - It "advertised" that it would help people stay out of the hospital and stay off a ventilator or die. It never "advertised" that it would make one immune and not catch covid-19. It has worked as "advertised." I was vaxed multiple times. I've caught covid twice. I hardly had any noticeable symptoms. I know folks who weren't vaxed and became very sick. Anedotal, in my case, but true to the "advertising."
- woodman: $PFE #LTInvestment And I know someone who was reasonably healthy, as far as I know, but he refused to get vaccinated. He caught covid-19 and died and left a family behind. Very sad.
- DavidK: @woodman $PFE #LTInvestment -per Joe Biden ( check the documented video and others on his staff) if you got the vax , you wouldn’t catch Covid . Bs I got 2 shots , caught it , got an infusion because I have had afib for years ( but had an ablation in March 2020 with ZERO afib flare ups ) until the infusion about killed me . Knocked my heart out of rhythm so badly I thought I was having a heart attack ). Many many many DRs I know including my father in law DR said no more . They knew the vac had heart related issues but pushed it anyway . It would have never ever passed FDA approval in its original form
- champ: @woodman $PFE #LTInvestment....I know couple of guys in their 80's, that aren't healthy, they smoked and drink and both that caught Covid twice and both were down for 2-weeks, with what they said was the worst flue that they ever had....and both were back playing golf after 3-weeks...... ....and I know many others that are in their 70's that also caught Covid...... and all had 3-shots. Many active golfers caught COVID, at my golf course, even the club mangers and all are doing find and one guy was 92 and another one was 95 and both are still shooting under their ages. It all depends on each person on how they do.
- DavidK: @champ $PFE #LTInvestment My Dr father in law just caught it and he is 91 and is he is doing fine so far .On Golf , I shot my age this past summer at Madison Country club in Ohio . 67. We have a summer home on Lake Erie and go up in summer . Brother there now last month snow hunting !
- champ: @DavidK $PFE #LTInvestment...#Nice-round, you must be a natural, I started playing golf are 52 and my best rounds ever were all at 72, could never get below that number because my head would always get in the way.
- wijimmy: @DavidK, @champ, @woodman, @margi1983, ...$PFE... To many Lawsuits in the works and coming soon...here are just 2 examples .. . George Watts died on October 27th, 2021 after collapsing in his room. An autopsy report from the Bradford County Coroner’s Office says he died from “COVID-19 vaccine-related myocarditis” which is an inflammation of the heart... . https://www.mytwintiers.com/news-cat/covid-19-vaccine-killed-our-son-says-lawsuit-against-dept-of-defense/ .. Texas Attorney General Paxton. “The facts are clear. Pfizer did not tell the truth about their COVID-19 vaccines. Whereas the Biden Administration weaponized the pandemic to force illegal public health decrees on the public and enrich pharmaceutical companies .. . .https://www.texastribune.org/2023/11/30/texas-attorney-general-pfizer-lawsuit/ . .https://www.texasattorneygeneral.gov/news/releases/attorney-general-ken-paxton-sues-pfizer-misrepresenting-covid-19-vaccine-efficacy-and-conspiring . .https://www.reuters.com/legal/pfizer-is-sued-by-texas-over-covid-19-vaccine-claims-2023-11-30/
- DavidK: @champ $PFE #LTInvestment #Nice-round played high school / jr college then at GA started Partying , no golf . Don’t play much 3 times a month . Gonna get back at it this spring . I did win club championship at 3 different clubs over the years though . Last 2 rounds 73-79
- phgruver: @DavidK $PFE #LTInvestment #Nice-round I did tell people to buy $PFE when it was below $28! Just sayin.....
- woodman: @wijimmy $PFE https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537923/#:~:text=They%20determined%20the%20number%20of,COVID%E2%80%9019%20in%20a%20year. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00320-6/fulltext https://www.cdc.gov/respiratory-viruses/whats-new/5-things-you-should-know.html https://www.cidrap.umn.edu/covid-19/report-covid-19-vaccines-saved-us-115-trillion-3-million-lives And on and on.
- Margi1983: @phgruver $PFE #LTInvestment #Nice-round Thanks phgruver. Let's keep this Forum focused on stocks not vaccine politics. My post at 2:10 PM today had nothing political, nothing about Covid, only the link to $PFE's 2024 guidance
- phgruver: @Margi1983 $PFE #LTInvestment #Nice-round ... I think you must have misread my post....
- phgruver: If anyone is interested, $PFE has filled the gap from 12/12/23, and is now trading above the closing price of the day before the gap down. These "bad news" selloffs are often buying opportunities. Almost all the members of the health care sector ($XLV) are trading near 52 week lows. For a long term, income oriented portfolio, this is something to consider, going into the new year.....
- DrScience: @phgruver $PFE Bad news selloffs *are* buying opportunities... Right up until they're not! Now, we need the stock to hold the 21 EMA and for the 8 EMA to cross from below as a signal that buyers continue to like the stock.
- phgruver: For anybody who might be considering income, $PFE was a buy on this pullback. I couldn't buy it on 12/13 or 12/14, because I didn't know where support was. Now, however, we know that support is $25.76, and that institutions are stepping in to pick up 6% income. There is still time to add this to your long term income portfolio, (unless you really believe that big pharma are a bunch of crooks who are out to make us all sick, and kill us with their drugs) as $PFE is bouncing along a multi-year lows. This company is not going out of business, just saying....
- Margi1983: @phgruver $PFE I agree. Good one for LT investment. I went long at $26.32 and intend to stay long.
- Motorman: @joelsg1 $GPCR $LLY Jeffries analyst said best in class should exceed 7%. But at least not pulled like $PFE candidate. Added at 28 to a small position.
- woodman: @Motorman $GPCR $LLY $PFE - $PFE needs an obesity asset. It will acquire someone, I speculate.
- Wolf: $PFE tried to fill the gap down, but got rejected.
- Wolf: $PFE Lowered #Guidance this AM. Down 6% PM. Down over 50% from 52 Wk high. 5.74% Div at this price if they don't cut it.
- phgruver: @Wolf $PFE #Guidance EPS in 2023 was $1.82, and they are projecting $2.05 to $2.25 for 2024. They also lowered guidance for revenues to $58.5B to $61.5B for 2024. That would seem to support the current dividend, without a problem. This may be a buying opportunity, but I wouldn't get in a hurry. Let's see how this settles out.
- traderbren: @Wolf $PFE #Guidance - yep, as I posted a few weeks back, it never ceases to amaze me how many so called "professional" penguins have come out pushing that $PFE is a buy over the last 2 months. They obviously don't know what a ski slope looks like. ;-) Maybe today is the turning point but I won't be the first guy out of the fox hole.
- phgruver: Possible bounce play with $PFE. The dividend is $0.41/qtr, which equates to 5.67% at this price. Unless you expect $PFE to totally collapse, this is a pretty good #VALUE entry for a solid income in a long term portfolio. $XLV, in general, is down near lows, although $LLY and $NOV seems to be bucking that trend. (I also own $ABBV and $BMY for income)
- traderbren: $PFE - not surprising how many Talking Heads on the Box have recommended $PFE all the way down...and it keeps heading south. Obviously, they don't know how to look at a chart!?! ;-)
- traderbren: @woodman $LLY - yep, I'm still long too. The news of the $PFE tab sounds like a good alternative to lose weight with side effects of puking & diarrhea! Yikes. ;-)
- woodman: $PFE relentlessly downward essentially since hitting its ath of $61 and change in Dec. 2021. It has pulled back to its 200 month ma, not that that's demonstrating any particular significance thus far. More interesting to me as a potential bounce area would be a re-visiting of its multi-bottom area of 26-27. But for now it continues to fall. No position.
- woodman: @Momentariness $MRNA - And $PFE, and $BNTX which moved even more. I caught none of them.
-
DAN: ...
[Note: You might also want to watch the COVID vax stocks. Apparently annual boosters are definitely a thing. The government is pumping them along with the annual flu shot, and I’m sure that there will be pervasive compliance by those who are ... - woodman: $ORIC - Moving well out of consolidation, up through $9 resistance. Lots going on with ORIC. I think its moving today on Baird's increased PT from $15 to $27, which is probably based on news regarding $PFE (a collaborator with ORIC). Recall that $PF ...
- jwstich: @woodman $ORIC $PFE $JNJ Thank you for your well done update. Been adding to this poition over the last few months. I really appreciate what you add to the forum and always raed your posts.
- woodman: @jwstich $ORIC $PFE $JNJ - Thank you. Much appreciated.
- bud_ozborn: I am seeing movement out of tech names and into pharma and banks RED $DDOG $SPLK $ARKK $CRWD green $ABT $LLY $BMY $MRK $PFE $KEY $PACW $SCHW $GS $STNE $NU
- vitoB: Took a look at diagnostic companies per a post on $MTD. But $DHR $TMO $A all have similar charts and might be a good candidate for sector rotation. Also in a similar light, cant believe that $PFE chart.
- woodman: @pperlroth $EFTR - Thanks for additional information. Two of their three programs/targets ((a) non-small cell lung cancer; (b) solid tumors/breast cancer/NSCLC) are in Phase 2 with topline data coming for (a) [Phase 2b] and dose escalation data for (b) [Phase 2a] this half of the year. Their third one also for solid tumors - on which they are working with Pfizer - is still in the pre-clinical stage. https://www.pfizer.com/news/press-release/press-release-detail/effector-enters-agreement-pfizer-inc-develop-novel-first- See also: https://effector.com/pipeline/ The CEO has good experience with some notable successes. He was involved with the acquisition of his previous venture, Anadys, by Roche for $230 million. He also was involved in the successful commercialization of HIV protease inhibitor that later acquired by $PFE.
- woodman: @joelsg1 $VKTX $ALT - I'm with you. I have only a small reminder position in VKTX as well. It's all about $LLY's obesity drug. Even $PFE out of favor now that it ditched one of its treatments in favor of a two a day pill, but is far behind on a one a ...
- woodman: $ORIC holding up well with a doji today after yesterday's strong move. I'm still in this. Remember that $PFE is partnered with ORIC (in ORIC-533 - which has data coming in 2H this year - anti-tumor activity from ongoing single agent Ph1b study in patients with multiple myeloma) and bought a bunch of ORIC stock at $4.65/share in December. PFE saw early data in the trial they partnered with. Its CSO for oncology and R&D joined $ORIC scientific advisory board. It knew what it was buying. There also was a private placement for big healthcare funds at a premium; participating investors entered into confidentiality agreements and executed lock-up agreements with ORIC to restrict their ability to sell ORIC shares. Lots of confidence here from big money. Riding the coattails.
- joelsg1: @woodman $VKTX $ALT $LLY $PFE $TERN Following your lead on these, but obvious concern that the Big Boys' oral formulations will swamp little guys like $VKTX. Also concerned about the thyroid cancer risks being studied, where hopefully $VKTX may have better profile.
- woodman: @joelsg1 $VKTX $ALT $LLY $PFE $TERN - Very valid concerns. And the small guys are years away. Perhaps a PFE type scoops one of them up in time. Not holding my breath. The need more data.
- woodman: @joelsg1 $VKTX $ALT $LLY $PFE $TERN - VKTX looks destined for the 11s-12s.
| Stock Price | $29.42 |
| Change | -0.81% |
| Volume | 56,865,300 |
Pfizer Inc is a research-based biopharmaceutical company. The Company has five operating segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health; and Consumer Healthcare.
Request Video of PFEAlready a member? Sign in here.
Past Month
Leading Peers
-
$24.39 59.00%
-
$8.03 33.05%
-
$15.61 16.85%
Past Month
Lagging Peers
-
$118.35 -25.40%
-
$7.86 -18.32%
-
$7.22 -14.78%
Dan Fitzpatrick
Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:
- Nightly video Strategy Sessions with a game plan for tomorrow
- Got a stock you want Dan to look at? Just ask.
- Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
- Access to over 90,400 stock analysis videos
- Access an ever expanding library (90,400) of educational videos that will save you time and make you money
Join a team of friends and traders that have one thing in common; a burning desire to succeed.
Become a Member Today!
Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...
Satisfaction Guaranteed!
Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!